Most of the published studies were focused on epidermal growth factor receptor (EGFR) alterations, which are the most commonly encountered actionable mutations in clinical practice, being present in 40–50% and 10–20% of NSCLC patients of Asian and non-Asian ethnicity, respectively [103,104,105]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.